The β-latch structural element of the SufS cysteine desulfurase mediates active site accessibility and SufE transpersulfurase positioning
Journal of Biological Chemistry · 2023
DOI: 10.1016/j.jbc.2023.102966 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2023. Verfasst von Rajleen K Gogar und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry & Biochemistry, The University of Alabama, Tuscaloosa, Alabama, USA. Hauptthemen laut MEDLINE: Carbon-Sulfur Lyases, Iron-Sulfur Proteins, Lyases, Escherichia coli Proteins. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, National Science Foundation, University of Alabama.
Abstract (Originalsprache)
Under oxidative stress and iron starvation conditions, Escherichia coli uses the Suf pathway to assemble iron-sulfur clusters. The Suf pathway mobilizes sulfur via SufS, a type II cysteine desulfurase. SufS is a pyridoxal-5'-phosphate-dependent enzyme that uses cysteine to generate alanine and an active-site persulfide (C364-S-S-). The SufS persulfide is protected from external oxidants/reductants and requires the transpersulfurase, SufE, to accept the persulfide to complete the SufS catalytic cycle. Recent reports on SufS identified a conserved "β-latch" structural element that includes the α6 helix, a glycine-rich loop, a β-hairpin, and a cis-proline residue. To identify a functional role for the β-latch, we used site-directed mutagenesis to obtain the N99D and N99A SufS variants. N99 is a conserved residue that connects the α6 helix to the backbone of the glycine-rich loop via hydrogen bonds. Our x-ray crystal structures for N99A and N99D SufS show a distorted beta-hairpin and glycine-rich loop, respectively, along with changes in the dimer geometry. The structural disruption of the N99 variants allowed the external reductant TCEP to react with the active-site C364-persulfide intermediate to complete the SufS catalytic cycle in the absence of SufE. The substitutions also appear to disrupt formation of a high-affinity, close approach SufS-SufE complex as measured with fluorescence polarization. Collectively, these findings demonstrate that the β-latch does not affect the chemistry of persulfide formation but does protect it from undesired reductants. The data also indicate the β-latch plays an unexpected role in forming a close approach SufS-SufE complex to promote persulfide transfer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry & Biochemistry, The University of Alabama, Tuscaloosa, Alabama, USA.
- Department of Chemistry & Biochemistry, The University of Alabama, Tuscaloosa, Alabama, USA. Electronic address: jadunkle@ua.edu.
- Department of Chemistry & Biochemistry, The University of Alabama, Tuscaloosa, Alabama, USA. Electronic address: pfrantom@ua.edu.
Förderung
- NIGMS NIH HHS
- National Science Foundation
- University of Alabama
- National Institutes of Health
Zitieren
APA
Gogar, R. K., Carroll, F., Conte, J. V., Nasef, M., Dunkle, J. A., & Frantom, P. A. (2023). The β-latch structural element of the SufS cysteine desulfurase mediates active site accessibility and SufE transpersulfurase positioning. Journal of Biological Chemistry. https://doi.org/10.1016/j.jbc.2023.102966
Vancouver
Gogar RK, Carroll F, Conte JV, Nasef M, Dunkle JA, Frantom PA. The β-latch structural element of the SufS cysteine desulfurase mediates active site accessibility and SufE transpersulfurase positioning. Journal of Biological Chemistry. 2023. doi:10.1016/j.jbc.2023.102966
BibTeX
@article{Gogar2023,
author = {Gogar, Rajleen K and Carroll, Franki and Conte, Juliana V and Nasef, Mohamed and Dunkle, Jack A and Frantom, Patrick A},
title = {The β-latch structural element of the SufS cysteine desulfurase mediates active site accessibility and SufE transpersulfurase positioning},
journal = {Journal of Biological Chemistry},
year = {2023},
doi = {10.1016/j.jbc.2023.102966}
}
EUVIMED